CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. - Test2 - elhamkhani - TriplyDB

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.

http://www.wikidata.org/entity/Q30437141

about

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy Perspectives on systems biology applications in diabetic kidney disease Human cervicovaginal fluid biomarkers to predict term and preterm labor Applications of urinary proteomics in biomarker discovery Mass spectrometry-based methods for identifying oxidized proteins in disease: advances and challenges A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.Ionization techniques in capillary electrophoresis-mass spectrometry: principles, design, and application.Biomarker analysis for prostate cancer diagnosis using LC-MS and CE-MS.Linking transcriptomic and proteomic data on the level of protein interaction networks.Application of Proteomic Analysis to Renal Disease in the Clinic.Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection.Urine collection and processing for protein biomarker discovery and quantification.Addressing the challenge of defining valid proteomic biomarkers and classifiers.Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling.Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Fibrinogen alpha chain precursor and apolipoprotein A-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease.Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population.Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.Mass spectrometry in chronic kidney disease research.Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.Detection of renal tissue and urinary tract proteins in the human urine after space flight.The Human Urinary Proteome Fingerprint Database UPdb.An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database.Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes Urine proteomic analysis in cystinuric children with renal stones.-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction.Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment.Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease.Prediction of acute coronary syndromes by urinary proteome analysis.

P2860

Q26752555-4DE462D6-D3CD-4EA4-8562-A10D9D207690 Q26823206-951F58A7-CEC6-490A-BD82-8B122D6F2E3F Q27000056-56103ABE-057F-4B16-9E90-A7F27B251ABB Q27010368-EF688CF0-AE3F-4B1E-8C6D-606E32C2BB01 Q28382957-6D4DDB5D-BB9C-4663-99C9-9FF3DB64604D Q28478586-995FC6AE-DE95-493E-B1EF-241619C3A296 Q28484968-7FDC3E2E-DEBA-4970-951E-A52635BBCC55 Q30434677-A4A869E8-1281-4115-BF70-33756683205F Q30438814-90A2B581-AE0D-43C7-B3DA-A0BEB5E05EE3 Q33436829-8957B310-A5D6-4E52-8C07-E6D70CF949C6 Q33449986-49CCF3FF-551C-486D-9683-173104B876E6 Q33451945-28B44407-A84D-4647-A5FE-99FB8A554743 Q33568802-CB1784F6-8147-40C8-84BC-70839C70290F Q33575004-472C4BE2-0B16-4571-B3D1-6126E39E882B Q33597457-1F3BB9E9-4189-4F16-83D5-EABD2BF3FD05 Q33603691-BF62795A-F3BC-4D77-AE0A-0ACED9072085 Q33735287-7AF2F762-D8AD-448D-AACA-5712E66BBFCC Q33748511-698E7DF4-2F67-463C-A045-18AEFEE53E57 Q33780855-AE21F944-A7FB-4465-BC33-17BD28FFF514 Q33786157-BF50D680-03C1-4616-AF66-DA57A25E7562 Q33797033-5DED7ADD-1378-4D44-992B-9FB78D89C0C2 Q33985444-74D8B7FE-5C9F-474C-A0CF-A6172D3C1CE9 Q34043307-7840A1F0-8309-4892-9646-B17E24DB3854 Q34129628-45BF9BC6-8DA1-4A86-95DD-DA868CCA0CA4 Q34140378-6D190CD2-0A8D-48D3-8FF8-8E748E482E3D Q34268714-B57336B0-3439-42FC-947E-3759DCC8F5F4 Q34313959-43638270-A1A0-46CF-B9D9-8E27DAE7D657 Q34725022-DD515F49-65A4-49DE-9F82-D59F399A0C34 Q34749242-8E20EDF1-7390-4EB9-A3F4-FAFABF69E44C Q34964281-F3D623BB-7DC6-4102-A20E-88ADCA83019D Q35040000-087EE88F-2781-41FC-BD97-88C25587F25A Q35423674-B22CC374-F6E1-42B1-B7EA-BD8A6674763B Q35579632-26FD0FF7-ED58-471E-9DE0-5F2FC26E10C6 Q35878999-F4C99BB7-758B-4145-BA05-1E7946292352 Q35967762-9B289F33-F8D1-4A9F-876E-37BF330C9C38 Q36016842-4524525C-318D-416F-828B-638331E70FF7 Q36053833-4B98182F-AB52-4A28-92F9-C28DA0E39EA0 Q36171255-7F107D16-2262-4E72-8703-F71155CC1BA5 Q36214366-04F8C15B-A290-48AD-BDA9-168691DCB6CA Q36300622-84A1FD17-D862-4452-8A2B-EAF9147C3C7B

P2860

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.

http://www.wikidata.org/entity/Q30437141

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@ast

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@en

type

label

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@ast

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@en

prefLabel

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@ast

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@en

P1433

Q30437141-8CE2B045-3110-4478-8DC4-3787E56762E0

P1476

Q30437141-187A1DAE-3911-4DE8-95FE-8C9E53EA9CAA

P2093

Q30437141-00D9B4E0-F375-43F4-AAC1-CED9E89AB047

Q30437141-0D199A7C-8644-4777-8722-DD788F156DBB

Q30437141-4C28BFEE-7981-40B7-B8AD-E10207A610D8

Q30437141-6E6C77A4-CB55-41E3-857D-5D1793A9A4B7

Q30437141-7D9A4259-0690-4F31-900C-16C6AE3AD75C

Q30437141-7F8B77C0-F54A-4728-BF51-E1BB1324DA87

Q30437141-89C1F8DC-2352-464D-BDBD-9278735DA998

Q30437141-91AC48FA-5A64-4FF6-983F-21264CCCDEE1

Q30437141-C2C29400-493E-45F0-926B-28B3479577A9

Q30437141-C4F1A26A-6E7C-403D-B685-287E39A0BD2F

P2860

Q30437141-06D635E0-C63E-49F0-BBAD-12F91EAE1369

Q30437141-07B8AC4B-F5D8-430A-989A-8905DE7E65EF

Q30437141-0B59D1D9-33B2-472A-A442-C0139B9D9AE6

Q30437141-11FB8238-3C6D-426A-991C-306BB3D140B9

Q30437141-16895C97-CA40-49D8-A32B-28E08F68B5EF

Q30437141-1D1088CF-D7C1-4CA8-8033-F889886161AE

Q30437141-232D5A70-2394-44FD-9907-CC07ACCCBC56

Q30437141-31E574C1-2A16-461D-8B04-0F82D5A42B7E

Q30437141-33E15E6B-675B-4CD4-9101-A45FD8CC59FB

Q30437141-353F1DF2-DDEB-440F-8CB6-70BBFF6481F5

P304

Q30437141-BA6AA795-B644-4DFD-8412-44502CFE7B9B

P31

Q30437141-3F940A05-3A9D-4CBE-8FE3-8E9C067F934E

P356

Q30437141-06558A57-F0F5-4B2F-9467-9113E219AF8E

P433

Q30437141-89CF203E-35F8-488C-8B16-2D48194F2FD2

P478

Q30437141-CF4099CD-3E5B-419A-A54A-D3AEDC294C4B

P50

Q30437141-14A396F4-819E-4BF9-BD2B-586CF70F0817

Q30437141-1A8D83A8-6C49-4398-A3CD-A36BF3E13DFB

Q30437141-6061EA68-729D-4ED8-9EFC-B8F00D2DCD20

Q30437141-85A1BF40-D211-48AF-A2F1-E7020F6FC94B

Q30437141-8D7132FD-6FFB-4F2F-B576-3E7F58D14AD8

Q30437141-A969490C-D60C-48EF-9D2E-600755F3F1D9

Q30437141-AF8B5094-FA87-49BF-8D84-916BD11B00A0

P577

Q30437141-5081A864-E92C-4D2A-B3DF-1B95729E7F17

P5875

Q30437141-2F2D2981-E653-412C-92BC-FF81CD9D5157

P698

Q30437141-67ED2882-58E3-4321-9E2F-4469862BFC81

P921

Q30437141-AC4B551A-A20C-40BF-8C39-7C6619E59066

P932

Q30437141-D5DAA110-5A4F-43C2-B933-DF1584BB9BAE

P356

P1433

Proteomics - Clinical Applications

P1476

CE-MS analysis of the human ur ...... overy and disease diagnostics.

@en

P2093

Bruce A Julian

http://www.w3.org/2001/XMLSchema#string

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

Danilo Fliser

http://www.w3.org/2001/XMLSchema#string

David M Good

http://www.w3.org/2001/XMLSchema#string

Eric Schiffer

http://www.w3.org/2001/XMLSchema#string

Eva M Weissinger

http://www.w3.org/2001/XMLSchema#string

Igor Golovko

http://www.w3.org/2001/XMLSchema#string

Jan Novak

http://www.w3.org/2001/XMLSchema#string

Joachim Jankowski

http://www.w3.org/2001/XMLSchema#string

Joshua J Coon

http://www.w3.org/2001/XMLSchema#string

P2860

Identifying differentially expressed genes using false discovery rate controlling procedures

Observations on the Liber medicine orinalibus by Hermogenes.

Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation.

Discovery and validation of urinary biomarkers for prostate cancer

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots.

Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry.

Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation.

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.

Mass spectrometric monitoring of albumin in uremia.

P304

964

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.200800024

http://www.w3.org/2001/XMLSchema#string

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Anna Dominiczak

Raymond Vanholder

Joost P Schanstra

Philippe Schmitt-Kopplin

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41405672

http://www.w3.org/2001/XMLSchema#string

P698

20130789

http://www.w3.org/2001/XMLSchema#string

P921

P932

2815342

http://www.w3.org/2001/XMLSchema#string